Phospho-SMC1A (S966) Antibody

What is SMC1A and what is the significance of its phosphorylation at serine 966?

SMC1A (Structural Maintenance of Chromosomes 1A) is a central component of the cohesin complex, which is essential for sister chromatid cohesion during DNA replication and repair. SMC1A plays critical roles in chromosome cohesion during cell cycle and DNA repair mechanisms. The protein is approximately 143-145 kDa and forms part of a large proteinaceous ring structure that holds sister chromatids together .

Phosphorylation of SMC1A at serine 966 (S966) occurs primarily in response to DNA damage, mediated by the ATM (Ataxia Telangiectasia Mutated) kinase. This specific phosphorylation event is a critical component of the DNA damage response pathway and serves as a downstream effector in both the ATM/NBS1 branch and the ATR/MSH2 branch of the S-phase checkpoint . The phosphorylation status of SMC1A at S966 is commonly used as a biomarker for activated DNA damage response pathways in research contexts.

What are the validated applications for Phospho-SMC1A (S966) antibodies in research?

Phospho-SMC1A (S966) antibodies have been validated for multiple research applications:

• Western Blot (WB): These antibodies reliably detect phosphorylated SMC1A at approximately 145 kDa in cell lysates, particularly after DNA damage induction with agents like camptothecin or etoposide. Different antibodies have optimized dilutions ranging from 1/5000 to 0.5 μg/mL .

• Immunocytochemistry/Immunofluorescence (ICC/IF): Phospho-SMC1A antibodies can visualize the nuclear localization of phosphorylated SMC1A in fixed cells, particularly after treatment with DNA damaging agents like hydroxyurea (3mM for 20h) .

• Immunoprecipitation (IP): These antibodies effectively isolate phosphorylated SMC1A complexes from cell lysates, as demonstrated with Jurkat cells treated with etoposide .

• Dot Blot: Phospho-specific antibodies like ab81306 have been validated for dot blot applications, confirming specificity by differentiating between phosphorylated and non-phosphorylated peptides .

The performance of these antibodies has been extensively validated in human cell lines including U2OS (osteosarcoma), HeLa (cervical adenocarcinoma), and Jurkat (T cell leukemia) cells .

How should I optimize Western blot protocols for detecting Phospho-SMC1A (S966)?

Optimizing Western blot protocols for Phospho-SMC1A (S966) detection requires attention to several critical factors:

• Sample preparation:

  • Include fresh phosphatase inhibitors in lysis buffers to preserve phosphorylation status

  • Use positive controls such as cells treated with DNA damaging agents (e.g., 1 μM camptothecin for 4 hours or 100 μM etoposide)

  • Consider including a lambda phosphatase-treated sample as a negative control to confirm phospho-specificity

• Gel electrophoresis and transfer:

  • Use lower percentage gels (6-8%) to better resolve the large SMC1A protein (approximately 145 kDa)

  • Optimize transfer conditions for large proteins using reduced methanol concentration

  • Use PVDF membranes for optimal protein binding

• Antibody incubation:

  • Follow recommended dilutions for specific antibodies:

    • R&D Systems AF2677: 0.5 μg/mL

    • Abcam ab81306: 1/5000 dilution

    • Abcam ab1276: 1/1000 dilution

  • Use 5% non-fat dry milk in TBST for blocking and antibody dilution

  • Incubate with primary antibody overnight at 4°C for optimal sensitivity

• Detection and analysis:

  • Use HRP-conjugated secondary antibodies with optimal dilutions (1/100,000 for some applications)

  • Adjust exposure times based on signal strength (3 minutes has been reported as effective)

  • Include proper controls for quantitative analysis

What positive and negative controls should I include when working with Phospho-SMC1A (S966) antibodies?

Proper controls are essential for reliable interpretation of Phospho-SMC1A (S966) data:

• Positive controls:

  • Cell lines treated with DNA damaging agents known to induce SMC1A phosphorylation:

    • Camptothecin (1 μM for 4 hours) - validated in U2OS cells

    • Etoposide (100 μM) - validated in Jurkat cells

    • Hydroxyurea (3 mM for 20 hours) - validated in HeLa cells

    • Neocarzinostatin - validated in SKN cells

• Negative controls:

  • Untreated cells showing baseline phosphorylation

  • Lambda phosphatase-treated samples to remove phosphorylation - this approach has been validated for confirming phospho-specificity

  • ATM/ATR inhibitor-treated cells to prevent SMC1A phosphorylation

• Specificity controls:

  • Peptide competition assays using phosphorylated versus non-phosphorylated peptides, as demonstrated with ab81306

  • Western blots should include molecular weight markers to confirm the expected 145 kDa band size

• Application-specific controls:

  • For Western blot: Include loading controls (β-actin, GAPDH)

  • For ICC/IF: Include secondary antibody-only controls and proper counterstains (DAPI for nucleus, tubulin for cytoskeleton)

  • For IP: Include IgG control immunoprecipitation

How can I confirm the phospho-specificity of my Phospho-SMC1A (S966) antibody?

Confirming phospho-specificity is crucial for validating experimental results with Phospho-SMC1A (S966) antibodies:

• Phosphatase treatment:

  • Treat a portion of your sample with lambda phosphatase

  • Compare antibody reactivity in treated versus untreated samples

  • A truly phospho-specific antibody will show decreased or absent signal in phosphatase-treated samples, as demonstrated with AF2677

• Peptide competition assay:

  • Pre-incubate the antibody with phosphorylated or non-phosphorylated peptides

  • A phospho-specific antibody will be blocked by the phosphorylated peptide but not by the non-phosphorylated version

  • This approach has been validated with ab81306 using dot blot analysis

• Drug-induced phosphorylation:

  • Compare antibody reactivity in untreated cells versus cells treated with DNA damaging agents

  • Significantly increased signal after damage induction confirms phospho-specificity

  • This has been demonstrated with various antibodies using camptothecin, etoposide, and hydroxyurea treatments

• Quantitative analysis:

  • Graph showing side-by-side comparison of signal intensity:

What are the common technical issues and troubleshooting approaches for Phospho-SMC1A (S966) antibody applications?

When encountering technical difficulties with Phospho-SMC1A (S966) antibodies, consider these troubleshooting strategies:

• Weak or absent signal:

  • Verify DNA damage induction using established markers (e.g., γH2AX)

  • Ensure phosphatase inhibitors are fresh and included in all buffers

  • Try different cell lysis methods to improve protein extraction

  • Increase antibody concentration or incubation time

  • Use more sensitive detection systems (enhanced chemiluminescence)

  • For Western blots, optimize transfer conditions for large proteins

• High background or non-specific binding:

  • Optimize blocking conditions (try 5% non-fat dry milk in TBST as recommended for ab81306)

  • Increase antibody dilution (1/5000 for Western blot with ab81306)

  • Add additional washing steps with higher stringency

  • For ICC/IF, optimize fixation and permeabilization (4% paraformaldehyde and 0.1% Triton X-100 have been validated)

• Inconsistent results between experiments:

  • Standardize treatment conditions (concentration and duration of damaging agents)

  • Maintain consistent sample handling procedures

  • Use the same lot of antibody when possible

  • Include quantifiable positive controls in each experiment

• Validation criteria table:

How can Phospho-SMC1A (S966) antibodies be used to study DNA damage response pathways?

Phospho-SMC1A (S966) antibodies serve as powerful tools for investigating DNA damage response (DDR) pathways through multiple experimental approaches:

• Temporal analysis of DDR signaling:

  • Conduct time-course experiments following DNA damage induction

  • Monitor the kinetics of SMC1A phosphorylation in relation to other DDR events

  • Establish the sequence of events in ATM/ATR signaling cascades

  • Compare phosphorylation patterns across different damage types (radiation, replication stress, chemotherapeutic agents)

• Spatial organization of repair processes:

  • Use immunofluorescence with Phospho-SMC1A (S966) antibodies in combination with other DDR proteins

  • Analyze the formation of nuclear foci and co-localization with damage sites

  • Confocal microscopy studies have demonstrated nuclear localization of phosphorylated SMC1A in HeLa cells treated with hydroxyurea

• Functional analysis through genetic or pharmacological interventions:

  • Compare SMC1A phosphorylation in cells with knockouts or inhibitors of specific DDR components

  • Establish dependency relationships between ATM/ATR and SMC1A phosphorylation

  • Correlate phosphorylation status with cellular outcomes (cell cycle arrest, repair efficiency, survival)

• Checkpoint regulation studies:

  • Investigate how SMC1A phosphorylation contributes to S-phase checkpoint activation

  • Combine with cell cycle analysis techniques to correlate phosphorylation with cell cycle progression

  • Recent research indicates that ATM phosphorylation of cohesin proteins, including SMC1A, is required for repression of both RNA transcription and DNA replication during damage response

What is the role of SMC1A phosphorylation in the regulation of transcription and replication during DNA damage?

Recent research has revealed critical functions of phosphorylated SMC1A in coordinating cellular processes during DNA damage response:

• Transcriptional regulation:

  • ATM phosphorylation of cohesin proteins, including SMC1A, SMC3, and PDS5A, is required for repression of RNA transcription during DNA damage response

  • This phosphorylation likely modifies cohesin's interaction with transcriptional machinery

  • Phosphorylated SMC1A may recruit chromatin modifiers to regulate gene expression

• Replication control:

  • SMC1A phosphorylation is implicated in the repression of DNA replication during damage response

  • This contributes to the intra-S phase checkpoint activation

  • The phosphorylated form may prevent new origin firing while protecting existing replication forks

• Integrated response coordination:

  • The dual role in regulating both transcription and replication suggests SMC1A phosphorylation serves as a coordinating mechanism during DNA damage

  • This provides cells with a unified response to genomic threats

  • The timing of SMC1A phosphorylation correlates with these regulatory events

• Experimental approaches to study these functions:

  • Chromatin immunoprecipitation (ChIP) with Phospho-SMC1A antibodies to identify genomic binding sites

  • Nascent RNA synthesis assays to measure transcriptional changes

  • DNA fiber analysis to assess replication dynamics

  • Integration with other genomic approaches (RNA-seq, ATAC-seq) to build comprehensive models

How does SMC1A phosphorylation at S966 interact with other post-translational modifications and DNA repair proteins?

SMC1A phosphorylation at S966 functions within a complex network of post-translational modifications and protein interactions:

• Interaction with DNA repair proteins:

  • Phosphorylated SMC1A interacts with BRCA1 during DNA damage response

  • This interaction facilitates recruitment of repair factors to damage sites

  • The phosphorylation status influences the strength and dynamics of these interactions

• Coordination with other phosphorylation events:

  • SMC1A is phosphorylated at multiple sites (S966, S957) by ATM and ATR kinases

  • These phosphorylation events work in concert to regulate cohesin function

  • The temporal sequence of phosphorylation may determine functional outcomes

• Relationship with the cohesin complex:

  • SMC1A phosphorylation affects the stability and chromatin association of the entire cohesin complex

  • Other cohesin components (SMC3, PDS5A) are also phosphorylated during damage response

  • These coordinated modifications reshape cohesin function during repair

• Methodological approaches to study interactions:

  • Co-immunoprecipitation using Phospho-SMC1A (S966) antibodies followed by mass spectrometry

  • Proximity ligation assays to detect protein-protein interactions in situ

  • Fluorescence resonance energy transfer (FRET) to analyze dynamic interactions in living cells

  • Comparative analysis of interactomes before and after DNA damage induction

How should I quantify and interpret changes in Phospho-SMC1A (S966) levels in experimental contexts?

Accurate quantification and interpretation of Phospho-SMC1A (S966) data requires rigorous analytical approaches:

• Western blot quantification methods:

  • Use densitometry software (ImageJ, Image Lab) to measure band intensities

  • Normalize phospho-SMC1A signal to total SMC1A to account for expression differences

  • When analyzing multiple conditions, calculate fold change relative to control

  • Present data with statistical analysis across at least three biological replicates

• Immunofluorescence quantification:

  • Measure nuclear fluorescence intensity in sufficient cell numbers (>100 per condition)

  • Set consistent thresholds for all experimental conditions

  • Consider both intensity and distribution patterns (pan-nuclear vs. focal)

  • Automated high-content imaging can provide robust quantitative data

• Expected patterns after DNA damage:

  • Rapid increase in phosphorylation within 15-30 minutes after damage

  • Peak levels typically at 1-2 hours post-damage

  • Signal strength proportional to damage severity

  • Characteristic nuclear localization pattern, as shown in HeLa cells treated with hydroxyurea

• Interpretation framework:

How can I correlate SMC1A phosphorylation with cell cycle phases and checkpoint activation?

Understanding the relationship between SMC1A phosphorylation, cell cycle, and checkpoint activation provides critical context for experimental data:

• Cell cycle-specific patterns:

  • S-phase cells typically show higher baseline SMC1A phosphorylation

  • DNA damage during S-phase produces robust SMC1A phosphorylation

  • This correlates with the role of SMC1A in the intra-S phase checkpoint

• Experimental approaches for cell cycle correlation:

  • Synchronize cells at different cell cycle phases before damage induction

  • Use flow cytometry to correlate phospho-SMC1A levels with DNA content

  • Perform double immunostaining for phospho-SMC1A and cell cycle markers

• Checkpoint activation assessment:

  • Measure BrdU incorporation or EdU labeling to evaluate S-phase checkpoint

  • Correlate SMC1A phosphorylation with cell cycle arrest

  • Compare with other checkpoint markers (phospho-Chk1, phospho-Chk2)

• Functional outcomes to monitor:

  • Cell cycle progression rates after damage

  • DNA repair efficiency using γH2AX resolution kinetics

  • Chromosomal stability through metaphase spread analysis

  • Cell survival through colony formation assays

• Research findings indicate that SMC1A phosphorylation contributes to the repression of both transcription and replication during the DNA damage response , consistent with its role in checkpoint activation.

What are the emerging research directions for Phospho-SMC1A (S966) in genomic stability and disease?

Current research is expanding our understanding of Phospho-SMC1A (S966) in multiple biological contexts:

• Role in genome maintenance mechanisms:

  • Beyond classical DNA repair, phosphorylated SMC1A contributes to replication fork protection

  • Involvement in resolving transcription-replication conflicts

  • Function in maintaining chromosomal architecture during stress conditions

  • Recent findings highlight its requirement for repression of both RNA transcription and DNA replication during damage response

• Cancer implications:

  • Altered SMC1A phosphorylation patterns in various cancer types

  • Potential biomarker for DNA damage response defects in tumors

  • Correlation with response to DNA-damaging chemotherapeutics

  • Research tools like phospho-specific antibodies enable these investigations

• Cellular stress responses beyond DNA damage:

  • Role in replication stress resolution

  • Function during mitotic challenges

  • Involvement in chromatin changes during major cellular transitions

• Methodological advances:

  • Development of more specific antibodies for different phosphorylation sites

  • Application in single-cell analysis techniques

  • Integration with genomic approaches (ChIP-seq, Hi-C)

  • Use in patient-derived samples for translational research

• Future research directions:

  • Investigating the dynamics of SMC1A phosphorylation in living cells

  • Exploring the interplay between different SMC1A phosphorylation sites

  • Developing strategies to modulate SMC1A phosphorylation for therapeutic purposes

  • Understanding tissue-specific functions of phosphorylated SMC1A